Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: kha vu who wrote (78677)	1/12/2000 10:32:00 AM
From: vagabond	Read Replies (2) \| Respond to of 120523

This HYSQ news sounds awfully important, but price hasn't reflected it yet (so far, down from opening). Not sure if it just hasn't been noticed yet, or if nobody cares for some strange reason... ====================== Wednesday January 12, 7:31 am Eastern Time Company Press Release SOURCE: Hyseq, Inc. Hyseq Announces DNA Sequencing Chip Breakthrough; More than 3,000 Bases of Any Gene Can Be Sequenced in a Single Reaction - Major Advance in SNP Detection SUNNYVALE, Calif., Jan. 12 /PRNewswire/ -- Hyseq, Inc. (Nasdaq: HYSQ - news) announced today a major advance that allows its DNA sequencing chip to sequence more than 3,000 bases of any gene in a single reaction. This read length is at least three times longer than produced by traditional gel-based technologies, the only other technology capable of sequencing any gene without using a specific reference gene or sequence. Because Hyseq's biochip reads every base, it is capable of detecting all mutations in a single reaction. Other biochips in the market are designed for specific genes and are not able to detect every possible single nucleotide polymorphism (SNP). Hyseq believes that this new advance makes its biochip a powerful tool for large-scale SNP and other polymorphism detection. Hyseq biochips, including those with this advanced technology, can be used in off-the-shelf commercial readers. ``With this advance, we can use a single type of biochip to determine a sequence or to detect any polymorphism,' said Radoje Drmanac, Hyseq's Chief Scientific Officer. ``We believe that our biochip's ability to detect any of the millions of human SNPs will make it an important tool in pharmacogenomics and for diagnostic use in personalized medicine. Because our biochips can sequence any gene in long reads, we believe our chip also will have great value in identifying specific microbial pathogens associated with disease (such as E. coli) or with biological warfare,' added Dr. Drmanac. ``Biochip designs that require a reference sequence, including those that do SNP analysis, may need to secure rights in the reference sequence. The advanced technology Hyseq uses to determine the sequence of any DNA sample may allow our biochips to detect polymorphisms or mutations in patient samples without using gene sequences that may be owned by others, thereby avoiding this pitfall,' said Lewis S. Gruber, Hyseq's President and Chief Executive Officer. ``With the gene race coming to an end, new biochips will be used to make use of this enormous amount of new information. Hyseq alone has analyzed over 12 million human DNA samples, resulting in the filing of patent applications on over 840,000 partial and full gene sequences. Specifically for biopharmaceutical applications, Hyseq has identified over 35,000 genes containing either secretory signal peptide segments or having significant homology to known genes, more than 5,000 of which have been completely sequenced,' Mr. Gruber added. Hyseq intends to make available gene sequences and tissue expression and homology data from its collection of proprietary genes through the GeneSolutions(TM) Portfolio of its wholly-owned subsidiary, GeneSolutions Inc. GeneSolutions.com also offers Hyseq the opportunity to directly market its biochips and other products online. The proprietary advances announced today are versatile enough to be used with other products, such as microbead devices, under development at Hyseq and elsewhere. Hyseq scientists pioneered Hyseq's high-throughput, SBH technology in the 1980s and the first patents covering the technology was issued in April 1993. Hyseq's scientists first reported their ability to assemble DNA sequences, sometimes called ``de novo' sequencing, in a 1993 issue of Science (260:1649-52). Hyseq is a biopharmaceutical company with a growing pipeline of therapeutic and diagnostic product candidates with a primary focus on immunology, cardiovascular, and hemopoetic fields. Hyseq uses its proprietary technology with its partners for therapeutic and diagnostic target discovery and pharmacogenomics and polymorphism analysis, and in its DNA analysis tools such as the HyChip(TM) system. Information about Hyseq is available at www.hyseq.com or by phoning 408-524-8100. Hyseq's wholly-owned subsidiary, GeneSolutions Inc., offers genomic resources to pharmaceutical and biomedical researchers on the Internet at www.genesolutions.com.